Meridian Bioscience Stock To Go Ex-dividend Tomorrow (VIVO)

NEW YORK ( TheStreet) -- The ex-dividend date for Meridian Bioscience (Nasdaq: VIVO) is tomorrow, May 2, 2012. Owners of shares as of market close today will be eligible for a dividend of 19 cents per share. At a price of $20.57 as of 9:30 a.m. ET, the dividend yield is 3.7%.

The average volume for Meridian Bioscience has been 305,700 shares per day over the past 30 days. Meridian Bioscience has a market cap of $857.7 million and is part of the health care sector and drugs industry. Shares are up 9.1% year to date as of the close of trading on Monday.

Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for gastrointestinal, foodborne, viral, respiratory, and parasitic infectious diseases. The company's diagnostic products primarily consist of C. The company has a P/E ratio of 27.7, below the average drugs industry P/E ratio of 31 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Meridian Bioscience as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, impressive record of earnings per share growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. You can view the full Meridian Bioscience Ratings Report.

See our dividend calendar or top-yielding stocks list.

null

More from Markets

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet